Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 9/20 | 0.69 |
| ▸ | SRC | P12931 | 9/20 | 0.69 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.69 |
| ▸ | EGFR | P00533 | 7/20 | 0.69 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.69 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.69 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.69 |
| ▸ | ABL1 | P00519 | 7/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.62 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.62 |
| ▸ | KIT | P10721 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16287869 | 0.93 | SRC (0.73) | WEE1SRCFGFR1EGFRFGFR2 | |
| SCHEMBL16287166 | 0.91 | SRC (0.62) | WEE1SRCFGFR1EGFRFGFR2 | |
| SCHEMBL16986361 | 0.88 | FGFR1 (0.59) | WEE1SRCFGFR1EGFRFGFR2 | |
| SCHEMBL16986362 | 0.88 | FGFR1 (0.69) | WEE1SRCFGFR1EGFRFGFR2 | |
| SCHEMBL16986316 | 0.87 | WEE1 (0.69) | WEE1SRCFGFR1EGFRFGFR2 | |
| SCHEMBL16995179 | 0.87 | WEE1 (0.69) | WEE1SRCFGFR1EGFRFGFR2 | |
| SCHEMBL16287371 | 0.86 | SRC (0.74) | WEE1SRCFGFR1EGFRFGFR2 | |
| SCHEMBL16986341 | 0.86 | FGFR1 (0.57) | WEE1SRCFGFR1EGFRFGFR2 | |
| SCHEMBL16986353 | 0.86 | FGFR1 (0.54) | WEE1SRCFGFR1EGFRFGFR2 | |
| SCHEMBL16287793 | 0.85 | FGFR1 (0.56) | WEE1SRCFGFR1EGFRFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630962-B2 | 4-amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof | HOSPITAL CLINIC DE BARCELONA (ES) | 2017-04-25 | — | — | US | claimed |
| EP-3008063-B1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO(2,3-D)PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | INST QUÍMIC DE SARRIÁ CETS FUNDACIÓ PRIVADA (ES) | 2017-04-19 | — | — | EP | claimed |
| US-20160176866-A1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | INSTITUT QUÍMIC DE SARRIÁ, CETS FUNDACIÓ, PRIVADA (ES) | 2016-06-23 | — | — | US | claimed |
| EP-3008063-A1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | Institut Químic de Sarriá CETS Fundació Privada (ES) | 2016-04-20 | — | — | EP | claimed |
| WO-2015118110-A1 | PYRIDO[2,3-D]PYRIMIDINE-7(8H)-ONE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | INSTITUT QUÍMIC DE SARRIÁ, CETS FUNDACIÓ PRIVADA (ES) | 2015-08-13 | — | — | WO | claimed |
| EP-2905024-A1 | Pyrido[2,3-d]pyrimidine-7(8H)-one derivatives for the treatment of infections caused by Flaviviridae | Institut Quimic De Sarriá Cets, Fundació Privada (ES) | 2015-08-12 | — | — | EP | claimed |
| WO-2014198960-A1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | INSTITUT QUÍMIC DE SARRIÁ, CETS FUNDACIÓ PRIVADA (ES) | 2014-12-18 | — | — | WO | claimed |
| EP-2813504-A1 | 4-Amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof | Institut Quimic De Sarriá Cets, Fundació Privada (ES) | 2014-12-17 | — | — | EP | claimed |
| US-9630962-B2 | 4-amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof | HOSPITAL CLINIC DE BARCELONA (ES) | 2017-04-25 | — | — | US | disclosed |
| US-9630962-B2 | 4-amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof | HOSPITAL CLINIC DE BARCELONA (ES) | 2017-04-25 | — | — | US | disclosed |
| EP-3008063-B1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO(2,3-D)PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | INST QUÍMIC DE SARRIÁ CETS FUNDACIÓ PRIVADA (ES) | 2017-04-19 | — | — | EP | disclosed |
| EP-3008063-B1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO(2,3-D)PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | INST QUÍMIC DE SARRIÁ CETS FUNDACIÓ PRIVADA (ES) | 2017-04-19 | — | — | EP | disclosed |
| WO-2017013160-A1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-8-METHYL-2-(PHENYLAMINO)-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE FOR TREATMENT OF SOLID CANCERS | PANGAEA BIOTECH, S.L. (ES) | 2017-01-26 | — | — | WO | disclosed |
| EP-3120851-A1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-8-METHYL-2-(PHENYLAMINO)-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE FOR TREATMENT OF SOLID CANCERS | Pangaea Biotech S.L. (ES) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015118110-A1 | PYRIDO[2,3-D]PYRIMIDINE-7(8H)-ONE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | INSTITUT QUÍMIC DE SARRIÁ, CETS FUNDACIÓ PRIVADA (ES) | 2015-08-13 | — | — | WO | disclosed |
| EP-2905024-A1 | Pyrido[2,3-d]pyrimidine-7(8H)-one derivatives for the treatment of infections caused by Flaviviridae | Institut Quimic De Sarriá Cets, Fundació Privada (ES) | 2015-08-12 | — | — | EP | disclosed |
| EP-2905024-A1 | Pyrido[2,3-d]pyrimidine-7(8H)-one derivatives for the treatment of infections caused by Flaviviridae | Institut Quimic De Sarriá Cets, Fundació Privada (ES) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014198960-A1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | INSTITUT QUÍMIC DE SARRIÁ, CETS FUNDACIÓ PRIVADA (ES) | 2014-12-18 | — | — | WO | disclosed |
| EP-2813504-A1 | 4-Amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof | Institut Quimic De Sarriá Cets, Fundació Privada (ES) | 2014-12-17 | — | — | EP | disclosed |
| EP-2813504-A1 | 4-Amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof | Institut Quimic De Sarriá Cets, Fundació Privada (ES) | 2014-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176866-A1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | BCL6, BCL9, BCL3 | WEE1 3036/4885SRC 1641/4885FGFR1 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.